Loading...

BiVictriX Therapeutics Plc

BVX.L•LSE
Healthcare
Biotechnology
£10.00
£1.50(17.65%)

BiVictriX Therapeutics Plc (BVX.L) Stock Overview

Explore BiVictriX Therapeutics Plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap8.3M
P/E Ratio-2.72
EPS (TTM)$-0.04
ROE-0.91%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$8.02

BVX.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BiVictriX Therapeutics Plc (BVX.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $8.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.72 and a market capitalization of 8.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for BVX.LStats details for BVX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for BVX.LAnalyst Recommendations details for BVX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.

CEO

Tiffany Jane Thorn

Employees

17

Headquarters

Bio Hub, Macclesfield

Founded

2021

Frequently Asked Questions

;